Chapter

PromiseXDisclosure

Mike Fortun

in Promising Genomics

Published by University of California Press

Published in print February 2008 | ISBN: 9780520247505
Published online March 2012 | e-ISBN: 9780520942615 | DOI: http://dx.doi.org/10.1525/california/9780520247505.003.0017
PromiseXDisclosure

Show Summary Details

Preview

The many stories about genomics which increasingly appear on television, in newspapers and magazines, and on the Internet reinforce the standard story that this is an industry based on “genetic information.” Genetic information, it is said, will provide a foundation for new drugs, new diagnostic kits, and new forms of therapy. But to the extent that the genomic industry is “based” on anything, it would be more accurate to say that it is based on the promise of genetic information—based on what genetic information may become in an anticipated, contingent, and open future. This begins to account for why the value of companies such as Celera Genomics, Millennium Pharmaceuticals, Incyte Genomics, and deCODE Genetics are “story stocks,” dependent not only on genetic technologies but on that other set of technologies for simultaneously producing and evaluating anticipated, contingent futures: literary technologies. Genomic companies, like their dot-com cousins that also emerged in the speculative economy of the 1990s, operated in the discursive space of the Private Securities Litigation Reform Act of 1995. The U.S. Securities and Exchange Commission makes disclosure necessary.

Keywords: Private Securities Litigation; Securities and Exchange; disclosure; promise; genomics; genetic information; deCODE Genetics; story stocks; literary technologies; genomic companies

Chapter.  5499 words. 

Subjects: Evolutionary Biology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.